INOVIO has appointed two senior executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic. Gene Kim joins the company as President of INOVIO Asia, LLC, a wholly-owned subsidiary of INOVIO based in Seoul, Korea. Mr. Kim served as chief financial officer of several publicly traded Korean companies and successfully led a company through the initial public offering (IPO). Mr. Kim will report to Dr. J. Jose...